← Back to Search

111I-n panitumumab for Head and Neck Cancers

Phase 1

Waitlist Available

Led By Eben Rosenthal

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 15 days

Awards & highlights

Study Summary

This trial is studying a radioactive molecule called 111In-panitumumab as a possible way to find sentinel lymph nodes in people with head and neck squamous cell carcinoma.

Eligible Conditions

Head and Neck Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 15 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~15 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 15 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Assess the safety of 111In panitumumab as a molecular imaging agent in patients with HNSCC.

Secondary outcome measures

Compare sensitivity of systemic 111In panitumumab versus conventional local optical dye

Compare specificity of systemic 111In panitumumab versus conventional local optical dye

Trial Design

1Treatment groups

Experimental Treatment

Group I: 111-In panitumumabExperimental Treatment2 Interventions

The study drug (111In panitumumab) 5 mCi, allowable range 4.5 to 5.5 will be administered on Day 0, and subjects will undergo one 111In panitumumab SPECT/CT imaging anytime between Day 1 and Day of Surgery. Subjects will undergo surgical resection after infusion of 111In panitumumab.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,383 Previous Clinical Trials

17,333,877 Total Patients Enrolled

Eben RosenthalPrincipal InvestigatorStanford Universiy

1 Previous Clinical Trials

27 Total Patients Enrolled

Fred Baik, MDPrincipal InvestigatorStanford Universiy

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the upper limit of participants in this clinical trial?

"Affirmative, the clinical trial is still recruiting candidates. It was initially listed on March 30th 2021 and has been amended as recently as March 11th 2022. The study requires 28 participants to be enrolled at one site."

Answered by AI

Have past experiments with 111I-n panitumumab been documented?

"At present, 33 trials are currently underway to study the efficacy of 111I-n panitumumab. Three of these studies have entered Phase 3 while most others can be found in Nagoya-shi, Aichi. In total, 561 sites are running investigations with this medication."

Answered by AI

Is this an unprecedented investigation into a medical condition?

"111I-n panitumumab was first studied in 2011 by Amgen. Following this initial clinical trial involving 75 participants, the drug received its Phase 2 approval. Now 33 active trials are underway across 141 cities and 15 countries worldwide."

Answered by AI

What potential adverse reactions accompany 111I-n panitumumab administration?

"After careful evaluation, our team has deduced that 111I-n panitumumab is comparatively less safe than other treatments. This conclusion was made because of the Phase 1 status of this trial, which implies limited data on its efficacy and safety."

Answered by AI

Does this clinical trial currently invite participants?

"Affirmative. According to information on clinicaltrials.gov, enrollment is still open for this particular study which was first posted on March 30th 2021 and updated more recently on March 11th 2022. 28 participants are being sought from one individual medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer

2021. "Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04840472.